Table 3
Patient characteristics (thrombolytic treatment)
| Thrombus location | Estimated thrombus age | Thrombolytic agent | Dose administered | Duration of treatment | Short-term outcome | ||||
|---|---|---|---|---|---|---|---|---|---|
| Unilateral femoral artery | 1 day | t-PA | 1.5 mg/kg/day | 2 days | Complete patency | ||||
| Unilateral femoral artery3-150 | ? | t-PA | 0.5 mg/day | 3 days | Complete patency | ||||
| External iliacal artery/abdominal aorta | 3 days | t-PA** | 7.2 mg/kg/day | 9 hours | Failure | ||||
| 3.6 mg/kg/day | 3 days | ||||||||
| Unialteral femoral artery | 3 days | UK | 4000 U/hour | 3 days | Complete patency | ||||
| Unilateral brachial artery | ? | t-PA† | 1.4 mg/kg/day | 10 days | Complete patency | ||||
| Bilateral external iliacal arteries | Connatal | t-PA | −12 mg/kg/day | 30 days | Partial patency | ||||
-
t-PA: recombinant tissue type plasminogen activator; UK: urokinase.
-
↵3-150 Associated with central line; ** bleeding from puncture sites; †cross-over from UK.
